Incyte Corp.

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the U.S., Canada, Europe and Japan.

Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.

The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.

Incyte is a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). The Leadership In MPNs and GVHD BEyond Ruxolitinib (LIMBER) program is designed to evaluate multiple monotherapy and combination strategies to improve and expand treatments for patients with MPNs and GVHD. The program currently has three key areas of focus: development of a new, once-daily formulation of ruxolitinib; ruxolitinib-based combinations with new targets such as PI3Kδ, BET and ALK2; and new therapeutic options such as Mutant CALR.